Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [¹⁷⁷Lu]Lu-DOTA-TATE therapy.

ABSTRACT:

Purpose

While there are reports of treatment-related endocrine disruptions and catecholamine surges in pheochromocytoma/paraganglioma (PPGL) patients treated with [¹⁷⁷Lu]Lu-DOTA-TATE therapy, the spectrum of these abnormalities in the immediate post-treatment period (within 48 hours) has not been previously evaluated and is likely underestimated.

Methods

The study population included patients (≥18 years) enrolled in a phase 2 trial for treatment of somatostatin receptor (SSTR)-2+ inoperable/metastatic pheochromocytoma/paraganglioma with [¹⁷⁷Lu]Lu-DOTA-TATE (7.4 GBq per cycle for 1 - 4 cycles). Hormonal measurements [adrenocorticotropic hormone (ACTH), cortisol, thyroid stimulating hormone (TSH), free thyroxine (FT4), follicle stimulating hormone (FSH),

SUBMITTER: Gubbi S 

PROVIDER: S-EPMC10598842 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature